PD-1/VEGF Dominating Targeted Oncology Trials
The simultaneous blockade of the PD-1/PD-L1 immune checkpoint and the VEGF/VEGFR angiogenesis pathway has yielded striking data. In advanced Phase 3 Targeted Oncology Trials (NCT06712355), investigational therapies like BNT327 are being evaluated extensively against standard-of-care options like atezolizumab in extensive-stage small-cell lung cancer.
TROP2 and Emerging Targets in Solid Tumors
HER2 and TROP2-directed therapies are cementing their role in thoracic oncology. For example, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab recently demonstrated practice-changing progression-free survival in DESTINY-Breast09, setting a new 1st-line benchmark.
Hematological Trial Successes
While solid tumors dominate the landscape, T-cell engaging bispecifics continue to transform hematology. Combinations of CD19-directed ADCs with CD20/CD3 bispecifics are reporting exceptional complete response rates in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), proving the immense synergistic potential of these modalities.
References
- ClinicalTrials.gov. NCT06712355: Safety and Efficacy of BNT327 in Combination With Chemotherapy.
- AstraZeneca US Press Release (2025). DESTINY-Breast09 Trial Results for ENHERTU.